Thus far, the immune-modifying function of a CTLA4 inhibitor combined with an MUC1 mRNA nanovaccine in the tumor microenvironment (TME) of triple-negative breast cancer (TNBC) has been evaluated by examining the cytotoxic immune cells and cytokines. This evidence concerns the gene MUC1 and neoplasm.